We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Amryt

News List

Amryt’s Myalepta scores NICE backing for rare lipid disorder pharmatimes
January 21, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Amryt Pharma’s Myalepta (metreleptin) for use within the NHS.
Green light for Amryt's epidermolysis bullosa study pharmatimes
January 08, 2019
An Independent Data Monitoring Committee (IDCM) has recommended that Amryt’s pivotal Phase III EASE trial for AP101 - a potential treatment for the currently incurable Epidermolysis Bullosa (EB) - should continue.
Amryt in-licenses novel gene therapy platform from UCD pharmatimes
July 23, 2018
UK biotech Amryt has secured itself access to a novel gene therapy platform that could give rise to a new treatment option for patients with Epidermolysis bullosa (EB), a group of rare inherited skin disorders that cause the skin to become very fragile.